Sanofi says Toujeo offers a similar blood glucose reduction to Lantus, with the added bonus of fewer cases of confirmed hypoglycaemia in patients at night – however this benefit was only ...

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...